




The relative strengths and weaknesses of GYRE Therapeutics INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of GYRE Therapeutics INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 180% points. The greatest weakness of GYRE Therapeutics INC is the variable Other Revenues, reducing the Economic Capital Ratio by 15% points.

The company's Economic Capital Ratio, given in the ranking table, is 408%, being 154% points above the market average of 254%.

Input Variable	Value in 1000 USD
Assets, Current	108,141
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	2,914
Liabilities, Non-Current	0
Other Assets	3,430
Other Compr. Net Income	-83
Other Expenses	3,802
Other Liabilities	0
Other Net Income	575
Other Revenues	275
Property and Equipment	428
Research and Development	19,499
Selling, General and Administrative Expense	10,172

Output Variable	Value in 1000 USD
Assets	111,999
Liabilities	2,914
Expenses	33,473
Revenues	275
Stockholders Equity	109,085
Net Income	-32,623
Comprehensive Net Income	-32,664
BaseVar	74,660
ECR before LimitedLiability	357%
Economic Capital Ratio	408%